If one injection can stop HIV for six months at almost 100 percent, why has it barely reached the countries with the most infections?
Welcome to FreeAstroScience. We read the trial papers and the rollout reporting side by side and ran the arithmetic the coverage skips, so you can see how a near-perfect HIV shot and fewer than 200,000 injections given across all of Africa belong to the same story.
Lenacapavir prevents HIV for six months per injection and reached 96 to 100 percent efficacy in the PURPOSE 1 and PURPOSE 2 trials, yet it has barely reached the hardest-hit countries, held back by price and politics rather than any doubt that it works. Fewer than 200,000 injections have been given across Africa so far, against a target of 3 million people by 2028 and 8 million already living with HIV in South Africa alone. Rich countries pay about 28,000 dollars a year for it, while generic versions priced near 40 dollars are not due before 2027.
According to the Science investigation into the rollout, a public clinic near Cape Town received 33 doses. They lasted three days. Every headline since 2024 has called this the most effective HIV-prevention tool ever made, and the trial data backs that up. Which is why 33 doses gone in three days is the number worth sitting with.
Twenty-five years, three ways to fight one virus
The fight against HIV has moved through three stages, and Lenacapavir is the third.
- Antiretroviral therapy arrived in the early 2000s and pushed the virus down to undetectable, which also made it untransmittable, the finding Science named its breakthrough of the year in 2011.
- Oral PrEP carried those same drugs into prevention from 2012, protecting HIV-negative people who take a pill every single day.
- Lenacapavir turned prevention into two injections a year, and after the 2024 trial results the FDA approved it for that use in June 2025 under the brand name Yeztugo.
Step three matters because of what went wrong with step two. A daily pill only works if it is already in your body, in enough quantity, at the moment you are exposed. Keeping that up for years is hard between side effects, forgetting, and stretches when the drug is simply out of stock, and that is why oral PrEP moved the infection numbers less than its efficacy promised in the places that needed it most. Truvada, the first PrEP pill, reached South Africa and Zambia only in 2016, four years after it went on sale in the United States.
What does Lenacapavir actually do to HIV?
Older HIV drugs jam a viral enzyme. Lenacapavir goes after the capsid instead, the protein shell that packs and protects the virus’s genetic core. A 2020 structural study by Stephanie Bester and colleagues, published in Science, showed the drug latching onto two neighboring capsid subunits and locking the shell’s shape, so the virus can neither slip its genome into the nucleus of a target cell nor build working new copies of itself. If you have read our piece on how the flu virus rewires the cells it infects, the logic is familiar: viruses live or die by hijacking host machinery, and a drug that jams the machinery wins.
Because it is injected under the skin and released slowly, one shot holds a protective level for six months, which takes the daily decision out of prevention altogether. PURPOSE 1 enrolled about 5,000 cisgender women in South Africa and Uganda and recorded zero infections in the lenacapavir arm. In PURPOSE 2, run across eight countries from Argentina to Thailand, only two people were infected, a 96 percent drop against daily Truvada.
So the drug works. Not the point. What matters is that a preventive almost nobody at risk can reach is both a real scientific win and a public-health non-event, and calling it the most effective HIV tool ever made, full stop, quietly drops the second half.
Where the injections actually went
South Africa carries the heaviest HIV burden on Earth, about 8 million people living with the virus and roughly 170,000 new infections a year, and it runs the world’s largest PrEP program. Its first consignment of Lenacapavir, delivered before the June 2026 launch, came to 37,920 doses spread across some 350 sites, which the Science rollout investigation put at about 10 percent of the country’s public clinics. Zambia received a little over 13,000. By the AIDS 2026 conference in July, the total given across the whole continent was nearly 200,000 injections.
Table 1 — Lenacapavir delivered against the HIV burden, first months of the African rollout (aidsmap and Science, July 2026).
| Place | The number that matters | Lenacapavir so far |
|---|---|---|
| South Africa | 8 million with HIV, ~170,000 new infections a year | 37,920 doses, first consignment |
| Zambia | 22 million people | just over 13,000 |
| Across Africa | target of 3 million people by 2028 | nearly 200,000 injections |
Now the part the headlines leave out.
Sit with those figures for a moment, because the arithmetic is unforgiving. A dose protects for six months, so South Africa’s 37,920 doses add up to roughly 19,000 person-years of protection, even if not a single one is wasted. Against 170,000 new infections a year, that covers about one person for every nine who will be newly infected. Across the continent, nearly 200,000 injections sit under 4 percent of the 5 million a year that campaigners say the drug needs to reach to change the epidemic.
We have watched this gap before. When we covered a gene-therapy breakthrough for a fatal childhood liver disease, the science was real and the treatment still had to prove it could reach a patient rather than a lab mouse. Lenacapavir is further along the road, proven in people rather than mice, and it is still stuck at the last step, the one where a working drug becomes a protected person.
Why do price and politics decide who gets protected?
Money is the first lock. Gilead lists the branded shot in the United States at 28,218 dollars a year. The same company has licensed six generic makers to sell a version for roughly 40 dollars a year across 120 low- and middle-income countries, close to a 700-fold cut, but those cheaper doses are not due before 2027. Between now and then, the countries with the most infections are asked to find the money at something near the rich-country price, or go without.
Politics is the second lock. For more than twenty years, much of the global HIV response ran through USAID and its PEPFAR program, which paid for testing, treatment, prevention, and health workers in the countries hit hardest. The Trump administration has dismantled USAID, and NPR reported the cuts tearing through South Africa’s prevention infrastructure just as the injection arrived. Pull the money out at that exact moment, and the best prevention tool ever made sits in a fridge.
A question hides underneath all of this, and it is one we keep circling in our essay on who really decides in modern medicine: a treatment’s worth is not settled in the trial. It is settled by whether the person who needs it can get it. A drug that clears every clinical bar and reaches almost no one has not yet done the thing it was built to do.
What we still cannot pin down
Some of the numbers are still moving, and honesty means saying which. The Africa-wide total is reported as “nearly 200,000” injections, and most of them are first doses, so how many people stay protected depends on whether the second shot arrives on schedule six months later. Efficacy of 96 to 100 percent came from trials that unblinded early, in mid-2024, and set to run until 2027, so the long-term durability and real-world adherence to a twice-a-year clinic visit are still being measured rather than known.
Two things are left out here on purpose. Injectable cabotegravir, the older long-acting option, gets no comparison from us, and the once-weekly islatravir and lenacapavir pill now in trials gets only this mention, because each deserves its own piece rather than a paragraph.
A working drug is not the same as a protected person
So here is where it stands. A six-month injection that reached up to 100 percent efficacy and recorded zero infections among the women of PURPOSE 1 has been given as fewer than 200,000 shots across Africa, enough for a small fraction of a single year’s need, while South Africa alone sees about 170,000 new infections a year. Blocking it is a 700-fold price gap that generics will not close before 2027, and a gutted USAID.
We wrote this out in full because the miracle-drug version hands you a number and asks you to be amazed, and you deserve the whole equation instead, the triumph and the empty fridge both. Our job here is to take the hard, unglamorous parts of a science story and hand them over whole, so you never switch your judgment off and swallow a headline. Doubt this. Check our arithmetic. If the rollout figures move, tell us we were too gloomy. We will come back to Lenacapavir when the low-cost generics are due in 2027, and we will count again. FreeAstroScience, Rimini. Gerd Dani.
Sources
- Bester, S. M., et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 370, 360-364 (2020). https://www.science.org/doi/10.1126/science.abb4808
- Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis, United States, 2025. MMWR, CDC. https://www.cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm
- Injectable Lenacapavir for PrEP, including PURPOSE 1 and PURPOSE 2 trial results. PrEPWatch, AVAC. https://www.prepwatch.org/products/lenacapavir-for-prep/
- Science’s 2024 Breakthrough of the Year: Opening the door to a new era of HIV prevention. Science, AAAS, December 2024. https://www.science.org/content/article/breakthrough-2024
- This drug could help end the HIV epidemic. Its rollout has hit speed bumps. Science, AAAS, 2026. https://www.science.org/content/article/drug-could-help-end-hiv-epidemic-its-rollout-has-hit-speed-bumps
- Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges. AIDS 2026 coverage, aidsmap. https://www.eatg.org/hiv-news/aids-2026-aidsmap-nearly-200000-lenacapavir-shots-given-across-africa-but-supply-issues-pose-challenges/
- South Africa Receives Lenacapavir, But Rollout Is Delayed (37,920-dose first consignment). Health-e News, 22 April 2026. https://health-e.org.za/2026/04/22/south-africa-receives-lenacapavir-but-rollout-is-delayed/
- South Africa rolls out game-changing HIV shot amid funding shortfalls. NPR, 5 June 2026. https://www.npr.org/2026/06/05/nx-s1-5846846/south-africa-hiv-lenacapavir-aid
- Deals promise cheaper generic lenacapavir for PrEP to 120 countries by 2027. Positively Aware. https://www.positivelyaware.com/articles/deals-promise-cheaper-generic-lenacapavir-prep-120-countries-2027-0
- Evangelista, G. G. Il Lenacapavir, il farmaco che puo fermare l’HIV ma non arriva a chi ne ha bisogno. Geopop, 2 August 2026 (the article that prompted this piece).
